Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 16/20 | 0.62 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113137 | 0.88 | ESR1 (0.49) | ESR1ESR2LTA4H | |
| SCHEMBL7110161 | 0.85 | ESR1 (0.53) | ESR1ESR2LTA4H | |
| SCHEMBL5431659 | 0.85 | LTA4H (0.51) | ESR1ESR2LTA4H | |
| SCHEMBL13389928 | 0.84 | ESR1 (0.82) | ESR1ESR2 | |
| SCHEMBL3122543 | 0.84 | ESR1 (0.82) | ESR1ESR2 | |
| SCHEMBL5426000 | 0.84 | LTA4H (0.47) | ESR1ESR2LTA4H | |
| SCHEMBL3122366 | 0.83 | ESR1 (0.63) | ESR1ESR2ENPP3ENPP1 | |
| Hydrochloric Acid SCHEMBL3106922 | 0.83 | ESR1 (0.82) | ESR1ESR2 | |
| SCHEMBL6238825 | 0.83 | ESR1 (0.42) | ESR1ESR2 | |
| SCHEMBL5420872 | 0.82 | LTA4H (0.51) | ESR1ESR2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530470-B9 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | LILLY CO ELI (US) | 2010-04-07 | — | — | EP | disclosed |
| US-7585977-B2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1530470-B1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | LILLY CO ELI (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080214612-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | DALLY ROBERT DEAN | 2008-09-04 | — | — | US | disclosed |
| US-7399867-B2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1782810-A2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | Eli Lilly & Company (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060183736-A1 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELILILLY AND COMPANY | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214612-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885ENPP3 1918/4885 |
| US-20060183736-A1 | Selective estrogen receptor modulators containing a phenylsulfonyl group | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885ENPP3 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.